Hamburg, Germany-based apoQlar designed VSI HoloMedicine to enable surgeons to plan complex procedures with 3D holographic technology.
According to a news release, FDA clearance makes the U.S. the 30th country to clear the apoQlar technology. The company intends to distribute in the U.S. through its Miami, Florida-based subsidiary. It expects commercial availability in the second quarter of 2023.
Following the clearance, apoQlar said it intends to raise a Series A funding round. It marks the medical metaverse company’s first-ever fundraising campaign as it looks to scale VSI HoloMedicine.
“With mixed reality, we are no longer bound to physical objects in a physical world,” said apoQlar co-founder and CEO Sirko Pelzl. “We ca…